UNSPSC 51142569: Rasagiline methanesulfonate

This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LH8C2JI290, chemically known as (r)-n-2-propynyl-1-indanamine methanesulfonate, but more generally known as rasagiline methanesulfonate, which bears US NIH Compound Identifier 3052775. European Medicines Agency schedules rasagiline methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10261MIG.

Most nations, for tariff purposes, schedule rasagiline methanesulfonate under HS 29214980. SMILES: CS(=O)(=O)O.C#CCN[C@@H]1CCC2C1CCCC2.

UNSPSC 51142569 Rasagiline methanesulfonate is a Commodity code that nominally designates a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows minimal direct relevance. The recent opportunities in the block reveal a mismatch: the Seminole County, Florida solicitation (IFB60459723LAS) procures naloxone and drug deactivation systems for community health; the Texas HHS RFI (HHS0017013) explores direct-to-manufacturer prescription fulfillment models; and the Minnesota Multistate Cooperative Purchasing Alliance solicitation (S1070000015802) seeks generic multi-source pharmaceuticals and over-the-counter products through three authorized wholesalers. None of these opportunities target rasagiline methanesulfonate or medications of comparable specificity. The issuing bodies span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances—a typical mix for pharmaceutical procurement—but they are soliciting broad pharmaceutical categories, not this narrow commodity.

The geographic spread indicated in the recent records includes Florida, Texas, and Minnesota, with Oregon also participating in the MMCAP cooperative. However, these opportunities do not establish that rasagiline methanesulfonate itself sees meaningful state and local procurement activity. The code shows little recent activity directly aligned with its nominal scope. A business development professional evaluating this code should treat it as inactive for state and local purposes or investigate whether catalog vendors and GPOs serving state and local health systems stock this medication under different procurement mechanisms or cooperative purchasing agreements not reflected in the solicitation block.